Brainsway (BWAY) has released an update.
BrainsWay Ltd. has announced FDA approval for expanded use of its Deep Transcranial Magnetic Stimulation (Deep TMS™) to treat major depressive disorder in patients aged 22 to 86, extending the previous limit of 68 years. This milestone marks the device as the first and only TMS tool approved for treating older patients with depression, potentially addressing the needs of an aging population. The company views this as a significant business opportunity, in line with increasing life expectancies and the demand for effective depression treatments in elderly individuals.
For further insights into BWAY stock, check out TipRanks’ Stock Analysis page.